FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

A panel of outside experts advising the US FDA backed the ​safety of Grail's blood-based cancer detection test, Galleri, ‌on Wednesday, but was divided on the evidence supporting its effectiveness.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。